NTLA

Canaccord Genuity Initiates Coverage of Intellia Therapeutics (NTLA) with Buy Recommendation

Fintel reports that on April 13, 2023, Canaccord Genuity initiated coverage of Intellia Therapeutics (NASDAQ:NTLA) with a Buy recommendation. Analyst…

2 years ago

Guru Fundamental Report for NTLA – Benjamin Graham

Below is Validea's guru fundamental report for INTELLIA THERAPEUTICS INC (NTLA). Of the 22 guru strategies we follow, NTLA rates…

2 years ago